Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in
June 26, 2025
No Comments